Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Tara Renée Heitner Hansen | M | 55 |
Abarceo AB
 Abarceo AB Miscellaneous Commercial ServicesCommercial Services Abarceo AB develops novel therapeutics for type-2 diabetes. It identifies a novel diabetes target located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to functional, preserving beta cell function and allowing patients to produce insulin naturally. The company was founded by Tara Heitner, Claes Wollheim, and Albert Salehi in December 2017 and is headquartered in Malmo, Sweden. | 7 anni |
| Annie Chandy | M | - |
Abarceo AB
Abarceo AB Miscellaneous Commercial ServicesCommercial Services Abarceo AB develops novel therapeutics for type-2 diabetes. It identifies a novel diabetes target located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to functional, preserving beta cell function and allowing patients to produce insulin naturally. The company was founded by Tara Heitner, Claes Wollheim, and Albert Salehi in December 2017 and is headquartered in Malmo, Sweden. | 7 anni |
| Albert Salehi | M | - |
Abarceo AB
Abarceo AB Miscellaneous Commercial ServicesCommercial Services Abarceo AB develops novel therapeutics for type-2 diabetes. It identifies a novel diabetes target located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to functional, preserving beta cell function and allowing patients to produce insulin naturally. The company was founded by Tara Heitner, Claes Wollheim, and Albert Salehi in December 2017 and is headquartered in Malmo, Sweden. | 7 anni |
| Ulrich Koch | M | - |
Abarceo AB
Abarceo AB Miscellaneous Commercial ServicesCommercial Services Abarceo AB develops novel therapeutics for type-2 diabetes. It identifies a novel diabetes target located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to functional, preserving beta cell function and allowing patients to produce insulin naturally. The company was founded by Tara Heitner, Claes Wollheim, and Albert Salehi in December 2017 and is headquartered in Malmo, Sweden. | - |
| Mathias Kroll | M | - |
Abarceo AB
Abarceo AB Miscellaneous Commercial ServicesCommercial Services Abarceo AB develops novel therapeutics for type-2 diabetes. It identifies a novel diabetes target located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to functional, preserving beta cell function and allowing patients to produce insulin naturally. The company was founded by Tara Heitner, Claes Wollheim, and Albert Salehi in December 2017 and is headquartered in Malmo, Sweden. | - |
Grafico relazionale
Relazione in diverse aziende
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Svezia | 5 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Claes Wollheim
- Contatti personali
